A Mayo Clinic study shows that over three decades, anxiety and depression have become more common in individuals with rheumatoid arthritis (RA).Data drawn from the Rochester Epidemiology Project identified incident adult RA (age >18 years) patients who were matched 1:1 with non-RA comparators. Depression and anxiety were defined by ICD9/10 codes.
Dr. John Cush RheumNow
1 year 9 months ago
Dr. Lindsey Criswell Elected to National Academy of Medicine. Dr. Criswell is the NIAMS Director and is known for her research in SLE, RA, and Sjogrens. Congrats!! https://t.co/3l4VHqnH2m https://t.co/FDcNVGjw4l
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
Dr. John Cush RheumNow
1 year 9 months ago
Manual labor jobs have more work disability in #PsA. 564 PsA pts, 29% were Blue collar; 71% White Collar. BCol (80% male) had more work disability at baseline (84% vs 28%; p < 0.01). Occupation did not influence DAS28-CRP remission at 1 yr, suggesting Rx response unaffected by… https://t.co/A9E5WZqIwu https://t.co/8PelrtpXco
Dr. John Cush RheumNow
1 year 9 months ago
Impact of biosimilars on biologic drug development pipelines. https://t.co/7kc0UDVPTy https://t.co/bPV3wAc2XY
Dr. John Cush RheumNow
1 year 9 months ago
Turkish retrospective review of 30 axSpA/PsA pts w/ Hx of prior malignancy and went on Rx w/ secukinumab betw 2018-2024. After mean F/U of ~ 30mo, SEC retention was 90% @12 mos & 81% @24 mos. There was only 1 local tumor recurrence w bladder carcinoma https://t.co/t7tqPtHOff https://t.co/wfAxwEsZLK
Dr. John Cush RheumNow
1 year 9 months ago
Alendronate Atypical Fractures Back In Court
Reuters reports that a U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck failed to warn that patients taking alendronate for osteoporosis may be at increased the risk of atypical femoral fractures.… https://t.co/DWXsFyzfWs https://t.co/HhROUArYBE
Dr. John Cush RheumNow
1 year 9 months ago
Economic and Mental Health Burden of Rheumatoid Arthritis
A University of Mississippi-led comprehensive study of a disorder that affects 4.27 million Americans nationwide is revealing just how significant its burdens are on patients' financial well-being and quality of life.… https://t.co/UpxHJSG6BL https://t.co/luPp1gjlRA
Dr. John Cush RheumNow
1 year 9 months ago
Biologic (bio-originators) & biosimilar serious Infx rates are low & similar. Retro Study w/ 2+ yrs F/U shows hosp. Infx to be 7% infliximab & 2% etanercept. Similar SIE w/ ETA IR = 11.8 (7.9, 16.8) vs 8.4 (6.9, 10.1) & INFLX SIE IR= 33.4 (27.2, 40.1) vs 29.3 (26.6,… https://t.co/i2rP88ofEP https://t.co/XBW4tLC8YH
Dr. John Cush RheumNow
1 year 9 months ago
Inadequate Zoster Vaccination in Immunocompromised Patients
A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.… https://t.co/EV24CQazex https://t.co/jiTuWQySgs
Dr. John Cush RheumNow
1 year 9 months ago
Is EBV relevant? It's certainly been linked to the etiol of SLE, RA, Sjögrens, & MS. Ronbinson et al suggests "EBV infection as a potentiator of autoimmune rheumatic diseases" and if Rx targeting of EBV may work in EBV-associated autoimmune diseases. https://t.co/bi630VvHTx https://t.co/tKYtwePaTu
Dr. John Cush RheumNow
1 year 10 months ago
NEJM Review Article on
"Cryoglobulinemia — One Name for Two Diseases "
(sign up for free read)
https://t.co/RFLKBeze3a https://t.co/eA3SLmPMdj
Dr. John Cush RheumNow
1 year 10 months ago
EULAR has announced its new, open access journal - EULAR Rheumatology Open (ERO) https://t.co/PWPXZ4H2Ku https://t.co/7kHcUpLFXD
Dr. John Cush RheumNow
1 year 10 months ago
Metanalysis of 40 papers, 486,465 RA pts & 3,928 incident ILD outcomes shows no signif risk of ILD w/ DMARD use; no ILD risk w/ TOFA or TNFi (Oral Surveillance n=2,911; OR 0.94). MTX use yielded a Lower ILD risk (OR 0.49; 0.32 to 0.76) vs no MTX use. https://t.co/Es8yyEiD8r https://t.co/qOYPkWNi9o
Dr. John Cush RheumNow
1 year 10 months ago
ANA+ consult? 2 Yr study of 207 asymptomatic ANA-pos, found only 11% progressed to systemic autoimmune rheum Dz (89% did not). Progressors developed SLE (48%), Sjögren (22%), scleroderma (13%), RA (4%); Arthritis (RR 1.74) more likly in progressors https://t.co/j54Vnsl50V https://t.co/jaPbigaqgS
